Connect with us

Health

Russia publishes virus vaccine results, weeks after approval – 570 News

Published

on


MOSCOW — Russian scientists have belatedly published first results from early trials into the experimental Sputnik V vaccine, which received government approval last month but drew considerable criticism from experts, as the shots had only been tested on several dozen people before being more widely administered.

In a report published in the journal Lancet on Friday, developers of the vaccine said it appeared to be safe and to prompt an antibody response in all 40 people tested in the second phase of the study within three weeks. However, the authors noted that participants were only followed for 42 days, the study sample was small and there was no placebo or control vaccine used.

One part of the safety trial included only men and the study mostly involved people in their 20s and 30s, so it is unclear how the vaccine might work in older populations most at risk of the more severe complications of COVID-19.

International experts remained cautious over the vaccine’s effectiveness and safety. Nevertheless, its Russian developers made some bold claims Friday after presenting the findings to reporters.

Professor Alexander Gintsburg, director of the Moscow-based Gamaleya Institute that developed the vaccine with assistance from Russia’s Defence Ministry, told reporters that the vaccine triggers “sufficient” immune response “to counteract any imaginable dose infecting (a person) with COVID-19.”

“We are ready to assert that the protective effect of this vaccine will be detectable and remain at a proper level for 2 years, or maybe even more,” Gintsburg said, without providing any evidence to back up the claim.

According to the Lancet report, the trials took place in two Russian hospitals involving healthy adults aged 18 to 60, who were required to self-isolate once they registered for the trial. They remained in the hospital for the first 28 days of the study after being vaccinated.

One part of the study involved a frozen formulation of the vaccine while another studied a freeze-dried variation. Scientists said the frozen vaccine would be suitable for current global vaccine supply chains while the freeze-dried version could be used in hard-to-reach areas.

Both vaccines used a modified version of the common cold-causing adenovirus to carry genes for the spike protein in the coronavirus, as a way to prime the body to react if a real virus causing COVID-19 comes along. That’s a similar technology to the vaccines being developed by China’s CanSino Biologics and Britain’s Oxford University and AstraZeneca.

Russian researchers said all 40 participants produced a neutralizing antibody response, molecules which are key to blocking infection. The vaccines also appeared to trigger a reaction in the body’s T-Cells, which help by destroying cells that have been invaded by the virus.

The most commonly reported side effects were pain at the injection site, fever, headache, and muscle or joint pain.

In an accompanying commentary, Dr. Naor Bar-Zeev of the Johns Hopkins Bloomberg School of Public Health and colleagues wrote that the studies were “encouraging but small.” They said that the immune reaction elicited by the vaccine “bodes well” but that “clinical efficacy for any COVID-19 vaccine has not yet been shown.”

Bar-Zeev and colleagues said that proving the safety of any coronavirus vaccine would be critical.

“Safety outcomes up to now are reassuring, but studies too date are too small to address less common, or rare serious adverse events,” they said. “Since vaccines are given to healthy people and during the COVID-19 pandemic, potentially to everyone after approval following (advanced) trials, safety is paramount.”

Dr. Ohid Yaqub, senior lecturer at the Science Policy Research Unit at the University of Sussex, said the limited study size was not enough for regulatory approval, which the vaccine received last month.

“In the context of regulatory approval, the design and size of (an early) study is not anywhere near sufficient for widely recognized standards of approval. The study was not randomized, and it was not large enough to detect rarer safety issues,” Yaqub said.

The vaccine was approved by the Russian government with much fanfare on Aug. 11. President Vladimir Putin personally broke the news on national television and said that one of his daughters had already been vaccinated, experienced slight side effects and developed antibodies. Since then, several high-profile officials also said they had taken the shots, including Moscow Mayor Sergei Sobyanin and Defence Minister Sergei Shoigu.

It remains unclear whether they were among the volunteers in clinical trials or accessed the vaccine in some other way.

Russian health authorities announced advanced trials of the vaccine among 40,000 volunteers last month. According to official records, it will be a randomized, double-blind, placebo-controlled study. Officials also mentioned that vaccination of risk groups, such as doctors and teachers, may be carried out “in parallel” — but it remains unclear whether it will be done as part of the study.

Michael Head, a senior research fellow in global health at Britain’s University of Southampton, agreed the Russian vaccine appeared to be “promising,” but that further studies were needed.

“At this stage, we do not actually know if the vaccine works,” he said. Head was not linked to the Russian research. “Public confidence in any vaccine is vital,” he said in a statement, calling suggestions from Russian and other authorities that a vaccine could be fast-tracked without the proper research “problematic.”

“Ultimately, we must not pour additional fuel on the anti-vaccine lobby fires,” he said.

__

Cheng reported from London.

___

Follow AP pandemic coverage at http://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak

Daria Litvinova And Maria Cheng, The Associated Press

Let’s block ads! (Why?)



Source link

Continue Reading

Health

Quebec reports 698 new COVID-19 cases, seven more deaths – Wiarton Echo

Published

on


That’s the highest single-day count since May 21.

Quebec has recorded 698 new cases of COVID-19 — the highest single-day count since May 21 — bringing the province’s total to 71,005 as of Saturday.

Seven new deaths have been reported, all of which occurred between Sept. 19 and 24. The province’s death toll now stands at 5,821.

The number of hospitalizations increased by 18, for a total of 217. Of those, 33 were in intensive care.

Related

All our coronavirus-related news can always be found at montrealgazette.com/tag/coronavirus.

Sign up for our email newsletter dedicated to local COVID-19 coverage at montrealgazette.com/coronavirusnews.

Help support our local journalism by subscribing to the Montreal Gazette here.

Let’s block ads! (Why?)



Source link

Continue Reading

Health

19 new coronavirus cases reported in Saskatchewan, hits single-day testing record – Global News

Published

on


Winnipeg police say a woman has died and several other people have been injured in a collision involving a vehicle that was fleeing police.

The crash happened at about 1:30 p.m. Saturday in the area of Salter Street and Boyd Avenue, police said in a statement.

According to police, officers tried to pull over a vehicle for a traffic stop but the driver “took off at a high rate of speed.”

Read more:
Vehicle-pedestrian collision on Portage Ave. leaves one person in critical condition

Seconds later, the vehicle hit another car in the nearby intersection of Andrews Street and Boyd Avenue.

Four people in the vehicle that was struck — including an infant and a child — were sent to hospital.  A woman who was in that vehicle has died from her injuries, police said.

Story continues below advertisement

Two people from the vehicle that had fled police were also transported to hospital.






0:24
No injuries reported after school bus crashes into hydro pole in downtown Winnipeg


No injuries reported after school bus crashes into hydro pole in downtown Winnipeg

The Independent Investigation Unit of Manitoba, which investigates serious incidents involving police, has been called to investigate.

In a press conference Saturday evening, Winnipeg Police Const. Rob Carver said that almost everyone in the collision was in either serious or critical condition.

“Incredibly tragic, we’ve got an infant in the vehicle, a child in the vehicle, a woman who was killed in this crash, tragic all around,” said Carver, who also stressed that the incident was not a result of a police pursuit.

A photo of the crash scene near Salter Street and Boyd Avenue.


A photo of the crash scene near Salter Street and Boyd Avenue.


Global News

“We pulled up, we attempted to have this vehicle spoken to, and the vehicle fled. We did not pursue it.”

Story continues below advertisement

For the two people in the fleeing vehicle, Carver said he does not have an idea on their injuries, but that they will at some point be taken into custody “when their medical condition allows for that.”

“In the space of less than half a minute … what started out as a routine incident ended up with multiple people in the hospital and a woman killed, and these people were not connected at all.”

— With files from Global News’ David Lao

© 2020 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)



Source link

Continue Reading

Health

Possible COVID-19 exposure at three Saskatoon businesses: SHA – CTV News Saskatoon

Published

on


SASKATOON —
The Saskatchewan Health Authority (SHA) is warning of a possible COVID-19 exposure at three Saskatoon businesses in the last week. 

The SHA said a person or persons attended the following locations while likely infectious:

• Sept. 19 – Walmart Supercentre at 225 Betts Ave. in Saskatoon from 4 to 6 p.m.

• Sept. 22 – Planet Fitness at Market Mall on 2325 Preston Ave. S in Saskatoon from 4 to 6 p.m.

• Sept. 23 – KFC at 1808 McOrmond Drive in Saskatoon from 5 to 10 p.m.

The SHA is advising anyone who was at these locations on the specified dates and times to self monitor for 14 days or immediately self isolate and call HealthLine 811 if they develop symptoms of COVID-19. 

People may develop symptoms between two and 14 days after getting exposed to the virus, according to the SHA.

Let’s block ads! (Why?)



Source link

Continue Reading

Trending